Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 23, 2025Annals of OncologyOpen Access

Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RBRobin BartoliniUniversity Hospital of LausanneLTLionel TruebUniversity of LausanneDDDouglas DaoudlarianUniversity Hospital of Lausanne

Discussion

Loading...

Member takes

Implication

Observational study reveals CD7+CXCR3+ CAR T-cell enrichment predicts durable remission in diffuse large B-cell lymphoma, suggesting product composition determines clinical outcomes.

Key Points

  • Identify predictive phenotypic and functional biomarkers within CAR T-cell infusion products linked to durable remission in patients with relapsed or refractory diffuse large B-cell lymphoma.
  • Single-center observational study conducted at Lausanne University Hospital in Switzerland analyzing infusion products and longitudinal 30-day peripheral blood samples from 13 patients with relapsed or refractory diffuse large B-cell lymphoma.
  • Profiled cellular phenotypes and functional markers using a 39-marker mass cytometry panel to compare long-term responders (n=8) against nonresponders (n=5).
  • Median progression-free survival reached 13.3 months (95% CI 9.7–24.3) in responders (n=8) versus 3.5 months (95% CI 0.5–5.4) in nonresponders (n=5) (HR 56.67, 95% CI 7.3–439.3, P=0.0001) at a median follow-up of 13.5 months.
  • Infusion products of responders showed significant enrichment of CD3+CXCR3+CD7+ CAR T-cells with elevated perforin, granzyme B, and NKG2D, whereas nonresponders displayed increased frequencies of CXCR3+CD7+LAG3+ cells along with elevated CD71 and Ki67.
  • A predictive model using cut-off ratios of CD3+CXCR3+CD7+LAG3+ (<0.83) and CD3+CXCR3+CD7+NKG2D+ (>1.034) CAR T-cells yielded a predictive accuracy of 0.92.

Cite This Study

Bartolini et al. (2025) studied this question.

synapsesocial.com/papers/6aa85ca6e43c8e8f383e16e1https://doi.org/10.1016/j.annonc.2025.03.011
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017 · 6,114 citations
  2. 2Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy2024 · 19 citations
  3. 3Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome2023 · 330 citations
  4. 4Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study2024 · 24 citations